Additional file 2: Figure S1. of Multipotent mesenchymal stromal cells from patients with newly diagnosed type 1 diabetes mellitus exhibit preserved in vitro and in vivo immunomodulatory properties

Showing the experimental design. Diabetes was induced in C57BL/6 male mice after daily intraperitoneal injections of 40 mg/kg STZ for 5 consecutive days. Twenty days after diabetes induction, mice were randomly divided into three experimental groups: Control-PBS group (diabetic mice treated with PBS; n = 6), C-MSCs group (diabetic mice treated with 1 × 106 MSCs isolated from healthy individuals; n = 9), and T1D-MSCs group (diabetic mice treated with 1 × 106 MSCs isolated from newly diagnosed T1D patients; n = 9). Nonfasting glucose blood levels were frequently determined. Thirty-five days after PBS/MSC administration, mice were sacrificed and different tissue samples were collected and analyzed. (TIFF 381 kb)